Eledon Pharmaceuticals, Inc. (ELDN) Investor Relations Documents

Eledon Pharmaceuticals, Inc. (ELDN) investor relations documents from the company's IR site: 5 presentations, 13 press releases; latest deck 2026-08-13. Read in-app with summaries. First-party data.

Eledon Corporate Presentation: Eledon Pharmaceuticals is developing tegoprubart, a novel anti-CD40L antibody, to replace toxic standard-of-care immunosuppressants in transplant medicine.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-13PresentationEledon Corporate Presentation
2026-08-13Press releaseEledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-06-25Press releaseNatera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
2026-06-22Press releaseEledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidn
2026-06-21PresentationAmerican Transplant Congress Data Update
2026-06-08Press releaseEledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1
2026-06-04Press releaseEledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patie
2026-05-20Press releaseEledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Reje
2026-05-13Press releaseEledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-03-19Press releaseEledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
2026-03-16Press releaseEledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1
2026-03-10Press releaseEledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejectio
2026-03-04Press releaseEledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference
2026-01-23Press releaseEledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American So
2026-01-08Press releaseEledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
2025-11-07PresentationEledon Pharmaceuticals Phase 2 BESTOW Tegoprubart Data at Kidney Week 2025
2025-08-06PresentationUpdated Data from Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
2025-07-09PresentationEledon Pharmaceuticals R&D Day Presentation – July 9, 2025

ELDN overview · ELDN earnings · ELDN financials · ELDN KPIs · ELDN ownership · ELDN peers · ELDN filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.